VolitionRx Inks Deal With Diagnostic Oncology CRO Over Nu.Q Products

VolitionRx has inked a deal with the contract research organization Diagnostic Oncology CRO to undertake clinical validation studies in the U.S. for VolitionRx’s tests for sepsis and cancer.

Initially, VolitionRx hopes the studies will support an application for the FDA’s Breakthrough Device designation for its Nucleosomics technology, leading to a potential submission in 2023. The technology identifies signatures of DNA circulating in the blood.

The studies will gather data on the clinical use of the company’s Nu.Q NETs and Nu.Q Cancer tests to support applications to the FDA for clearance, authorization or approval, the companies said.

The financial terms of the deal were not disclosed.